close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

34.69 -0.11 (-0.32%)
Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
News headline image
Volume Surges Spark Turnarounds for These 3 Stocks
There are countless historical chart examples of high volume moves that mark the beginning of sustained rallies or slumps. Let’s tune into a few examples. 
Via MarketBeat
Topics Lawsuit
News headline image
Teva Reports Second Quarter 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Appointment of New Global R&D and Chief Medical Officer
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)
From Teva Pharmaceutical Industries Ltd.
Via Business Wire
News headline image
Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reports First Quarter 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today